DocWire News Editors

DocwireNews

Pharmacists’ education on cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer is essential to assessing treatment options, differentiating trial results, and building confidence to manage adverse events (AEs). Researchers tested two educational programs to improve pharmacist understanding of these agents and found that they were beneficial. The results of the study were presented by Amy Seung, PharmD, BCOP, FHOPA, senior medical director at Pharmacy Times Continuing Education, at HOPA’s 16th Annual Conference.
Researchers launched two collaborative programs in January 2019. The first was a 2.5-credit hour print and digital article that incorporated cases with patient counseling videos. The case studies offered practice scenarios with decision trees to simulate real-world AE management. Five pre- and post-activity questions were developed to evaluate declarative and procedural knowledge before and after the educational initiative. The second was a 1.5-hour live virtual symposium hosted by expert faculty that used embedded counseling videos based on real-world scenarios into three settings of patient-centered pharmacist care: clinic, remote specialty pharmacy, and retail pharmacy. Videos highlighted significant AEs and therapy-specific challenges in each setting.
Researchers targeted oncology and specialty pharmacists in multiple practice settings. A total of 1,888 participants completed the activity and an evaluation to receive credit. The most common self-identified practice settings were retail (n=803; 42.5%), health system (n=479; 25.4%), and specialty pharmacy (n=226; 12.0%).
When comparing pre- and post-tests, case-based questions on counseling for a clinically significant interaction demonstrated a knowledge increase of 34% to 75% with the use of a video-embedded case and simulation. Before the activity, 51% of learners identified as moderately, very, or extremely confident in using treatment strategies for HR+/HER2– advanced breast cancer, and this increased to 85% post-activity.
“Education based on specific roles and practice settings is necessary to manage diverse needs, thus enhancing patient outcomes,” the authors concluded.
Reference 
Seung A, Mangini N, Roman D, et al. Innovative active learning increases confidence and knowledge of pharmacists managing CDK4/6 inhibitors in HR+/HER2– advanced breast cancer (BC). Presented at HOPA 16th Annual Conference. March 2020, Tampa, Florida.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Educational Programs Improve Pharmacist Confidence, Knowledge in Prescribing CDK4/6 Inhibitors for Breast Cancer

2020 HOPA Annual Conference

Pharmacists’ education on cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative breast ...

Educational Programs Improve Pharmacist Confidence, Knowledge in Prescribing CDK4/6 Inhibitors for

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe